AN ACT PROHIBITING CERTAIN LICENSEES AND REGISTRANTS FROM SELLING, DISPENSING, TRANSFERRING OR DELIVERING ANY DRUG OR DEVICE TO EXECUTE A COURT-IMPOSED SENTENCE OF DEATH.

LCO 1 of 20

General Assembly Substitute Bill No. 5225
February Session, 2026

AN ACT PROHIBITING CERTAIN LICENSEES AND REGISTRANTS
FROM SELLING, DISPENSING, TRANSFERRING OR DELIVERING
ANY DRUG OR DEVICE TO EXECUTE A COURT-IMPOSED
SENTENCE OF DEATH.
Be it enacted by the Senate and House of Representatives in General
Assembly convened:

Section 1. Section 21a -70 of the 2026 supplement to the general 1
statutes is repealed and the following is substituted in lieu thereof 2
(Effective October 1, 2026): 3
(a) As used in this section: [(1) "Drugs", "devices" and "cosmetics" 4
have the same meanings as defined in section 21a -92, "wholesaler" or 5
"distributor" means a person, including, but not limited to, a medical 6
device and oxygen provider, a third -party logistics provider, a virtual 7
manufacturer or a virtual wholesale distributor, as such terms are 8
defined in section 20-571, whether within or without the boundaries of 9
the state of Connecticut, who supplies drugs, devices or cosmetics 10
prepared, produced or packaged by manufacturers, to other 11
wholesalers, manufacturers, distributors, hospitals, prescribing 12
practitioners, as defined in section 20 -571, pharmacies, federal, state or 13
municipal agencies, clinics or any other person as permitted under 14
subsection (h) of this section, except that: (A) A retail pharmacy or a 15
pharmacy within a licensed hospital that supplies to another such 16
pharmacy a quantity of a noncontrolled drug or a schedule II, III, IV or 17
Substitute Bill No. 5225

LCO 2 of 20

V controlled substance normally stocked by such pharmacies to provide 18
for the immediate needs of a patient pursuant to a prescription or 19
medication order of an authorized practitioner, (B) a pharmacy within a 20
licensed hospital that supplies drugs to another hospital or an 21
authorized practitioner for research purposes, (C) a retail pharmacy that 22
supplies a limited quantity of a noncontrolled drug or of a schedule II, 23
III, IV or V controlled substance for emergency stock to a practitioner 24
who is a medical director of a chronic and convalescent nursing home, 25
of a rest home with nursing supervision, of a hospice inpatient facility 26
licensed pursuant to section 19a-491 or of a state correctional institution, 27
and (D) a pharmacy within a licensed hospital that contains another 28
hospital wholly within such licensed hospital's physical structure that 29
supplies to such contained hospital a quantity of a noncontrolled drug 30
or a schedule II, III, IV, or V controlled substance normally stocked by 31
such hospitals to provide for the needs of a patient, pursuant to a 32
prescription or medication order of an authorized practitioner, receiving 33
inpatient care on a unit that is operated by the contained hospital, or 34
receiving outpatient care in a setting operated by the contained hospital 35
and such drug or substance is administered on -site by the contained 36
hospital, shall not be deemed a wholesaler under this section; (2) 37
"manufacturer" means (A) a person, whether within or without the 38
boundaries of the state of Connecticut, who produces, prepares, 39
cultivates, grows, propagates, compounds, converts or processes, 40
directly or indirectly, by extraction from substances of natural origin or 41
by means of chemical synthesis or by a combination of extraction and 42
chemical synthesis, or who packages, repackages, labels or relabels a 43
container under such manufacturer's own or any other trademark or 44
label any drug, device or cosmetic for the purpose of selling such items, 45
or (B) a sterile compounding pharmacy, as defined in section 20 -633b, 46
that dispenses sterile pharmaceuticals without a prescription or a 47
patient-specific medical order; (3) "drug", "device" and "cosmetic" have 48
the same meanings as provided in section 21a -92; and (4) 49
"commissioner" means the Commissioner of Consumer Protection or 50
the commissioner's designee.] 51
Substitute Bill No. 5225

LCO 3 of 20

(1) "Commissioner" means the Commissioner of Consumer 52
Protection; 53
(2) "Cosmetic" has the same meaning as provided in section 21a-92; 54
(3) "Device" has the same meaning as provided in section 21a-92; 55
(4) "Distributor" or "wholesaler" (A) means a person, including, but 56
not limited to, a medical device and oxygen provider, a third -party 57
logistics provider, a virtual manufacturer or a virtual wholesale 58
distributor, as such terms are defined in section 20-571, whether within 59
or without the boundaries of the state of Connecticut, who supplies 60
drugs, devices or cosmetics prepared, produced or packaged by 61
manufacturers to other wholesalers, manufacturers, distributors, 62
hospitals, prescribing practitioners, as defined in section 20 -571, 63
pharmacies, federal, state or municipal agencies, clinics or any other 64
person as permitted under subsection (i) of this section, and (B) does not 65
include (i) a retail pharmacy or a pharmacy within a licensed hospital 66
that supplies to another such pharmacy a quantity of a noncontrolled 67
drug or a schedule II, III, IV or V controlled substance normally stocked 68
by such pharmacies to provide for the immediate needs of a patient 69
pursuant to a prescription or medication order of an authorized 70
practitioner, (ii) a pharmacy within a licensed hospital that supplies 71
drugs to another hospital or an authorized practitioner for research 72
purposes, (iii) a retail pharmacy that supplies a limited quantity of a 73
noncontrolled drug or of a schedule II, III, IV or V controlled substance 74
for emergency stock to a practitioner who is a medical director of (I) a 75
chronic and convalescent nursing home, (II) a rest home with nursing 76
supervision, (III) a hospice inpatient facility licensed pursuant to section 77
19a-491, or (IV) a correctional institution unless the correctional 78
institution has actual knowledge that the noncontrolled drug or 79
controlled substance will be used to execute a sentence of death imposed 80
by a court, and (iv) a pharmacy within a licensed hospital that contains 81
another hospital wholly within such licensed hospital's physical 82
structure that supplies to such contained hospital a quantity of a 83
noncontrolled drug or a schedule II, III, IV or V controlled substance 84
Substitute Bill No. 5225

LCO 4 of 20

normally stocked by such hospitals to provide for the needs of a patient, 85
pursuant to a prescription or medication order of an authorized 86
practitioner, receiving inpatient care on a unit that is operated by the 87
contained hospital, or receiving outpatient care in a setting operated by 88
the contained hospital and such drug or substance is administered on -89
site by the contained hospital; 90
(5) "Drug" has the same meaning as provided in section 21a-92; 91
(6) "Manufacturer" means (A) a person, whether within or without 92
the boundaries of the state of Connecticut, who produces, prepares, 93
cultivates, grows, propagates, compounds, converts or processes, 94
directly or indirectly, by extraction from substances of natural origin or 95
by means of chemical synthesis or by a combination of extraction and 96
chemical synthesis, or who packages, repackages, labels or relabels a 97
container under such manufacturer's own or any other trademark or 98
label any drug, device or cosmetic for the purpose of selling such items, 99
or (B) a sterile compounding pharmacy, as defined in section 20 -633b, 100
as amended by this act, that dispenses sterile pharmaceuticals without 101
a prescription or a patient-specific medical order; and 102
(7) "Person" means any individual, partnership, corporation, limited 103
liability company, association or other legal entity. 104
(b) No [wholesaler or manufacturer] person shall operate as [such] a 105
manufacturer or wholesaler until [he] such person has received a 106
certificate of registration issued by the commissioner, which certificate 107
shall be renewed annually, provided no such certificate shall be 108
required of a manufacturer, except a sterile compounding pharmacy, as 109
defined in subsection (a) of section 20 -633b, whose principal place of 110
business is located outside the state, who is registered with the federal 111
Food and Drug Administration or any successor agency and who files a 112
copy of such registration with the commissioner. A fee of one hundred 113
ninety dollars shall be charged for each wholesaler's certificate and 114
renewal thereof. A separate certificate and corresponding fee is required 115
for each location existing in this state and for each location existing 116
Substitute Bill No. 5225

LCO 5 of 20

outside of this state that distributes products into this state. The fee for 117
a manufacturer's certificate and renewal thereof shall be two hundred 118
eighty-five dollars for manufacturers employing not more than five 119
licensed pharmacists or qualified chemists or both; three hundred 120
seventy-five dollars for manufacturers employing not more than ten 121
licensed pharmacists or qualified chemists or both; and nine hundred 122
forty dollars for manufacturers employing more than ten licensed 123
pharmacists or qualified chemists or both. No such certificate shall be 124
issued to a manufacturer unless such drugs, devices or cosmetics are 125
manufactured or compounded under the direct supervision of a 126
licensed pharmacist or a qualified chemist. No certificate of registration 127
shall be issued under this section until the applicant has furnished proof 128
satisfactory to the commissioner that the applicant is equipped as to 129
facilities and apparatus to properly carry on the business described in 130
his application and that the applicant conforms to chapter 418 and 131
regulations adopted thereunder. 132
(c) The commissioner shall have the right to deny a certificate of 133
registration if [he] the commissioner determines that the issuance of 134
such registration is inconsistent with the public interest. In determining 135
the public interest, the commissioner shall consider, at a minimum, the 136
following factors: 137
(1) Any convictions or regulatory actions involving the applicant 138
under any federal, state or local law relating to drug samples, wholesale 139
or retail drug distribution, or distribution or possession of drugs 140
including controlled substances; 141
(2) Any felony convictions of the applicant under federal, state or 142
local laws; 143
(3) The applicant's past experience in the manufacture or distribution 144
of drugs; 145
(4) The furnishing by the applicant of false or fraudulent material in 146
any application made in connection with drug manufacturing or 147
distribution; 148
Substitute Bill No. 5225

LCO 6 of 20

(5) Suspension, revocation or other sanction by federal, state or local 149
government of any license or registration currently or previously held 150
by the applicant for the manufacture or distribution of any drugs; 151
(6) Compliance with licensing or registration requirements under 152
previously granted licenses or registrations; 153
(7) Compliance with requirements to maintain or make available to 154
the commissioner or to federal, state or local law enforcement officials 155
those records required by any federal or state statute or regulation; 156
(8) Failure to provide adequate control against the diversion, theft 157
and loss of drugs; 158
(9) Provision of required security for legend drugs and, in the case of 159
controlled substances, compliance with security requirements for 160
wholesalers set forth in regulations adopted under chapter 420b; [and] 161
(10) Manufacturing, selling or dispensing any drug or device with 162
actual knowledge that the person purchasing or receiving such drug or 163
device directly from the applicant intends to use such drug or device to 164
execute a sentence of death imposed by a court; and 165
[(10)] (11) Compliance with all regulations adopted to enforce the 166
provisions of this section. 167
(d) The commissioner may suspend, revoke or refuse to renew a 168
registration, or may issue a letter of reprimand or place a registrant on 169
probationary status, for sufficient cause. Any of the following shall be 170
sufficient cause for such action: 171
(1) The furnishing of false or fraudulent information in any 172
application or other document filed with the commissioner; 173
(2) Any criminal conviction of the registrant under any federal or 174
state statute concerning drugs; 175
(3) The suspension, revocation or other restriction or penalty issued 176
Substitute Bill No. 5225

LCO 7 of 20

against a license or registration related to drugs; 177
(4) Failure to provide adequate control against the diversion, theft 178
and loss of drugs; [or] 179
(5) Manufacturing, selling or dispensing any drug or device with 180
actual knowledge that the person purchasing or receiving such drug or 181
device directly from the registrant intends to use such drug or device to 182
execute a sentence of death imposed by a court; or 183
[(5)] (6) A violation of any provision of any federal or state statute or 184
regulation concerning drugs. 185
(e) The commissioner shall not issue or renew a certificate of 186
registration unless the applicant or registrant seeking such certificate or 187
renewal submits to the commissioner, in a form and manner prescribed 188
by the commissioner, a signed, written statement attesting t hat such 189
applicant or registrant shall not manufacture, sell or dispense any drug 190
or device with actual knowledge that the person purchasing or receiving 191
such drug or device directly from such applicant or registrant intends 192
to use such drug or device to execute a sentence of death imposed by a 193
court. 194
[(e)] (f) [Wholesalers and manufacturers ] Manufacturers and 195
wholesalers shall operate in compliance with applicable federal, state 196
and local statutes, regulations and ordinances, including any applicable 197
laws concerning controlled substances, drug product salvaging or 198
reprocessing. 199
[(f) Wholesalers and manufacturers ] (g) Manufacturers and 200
wholesalers shall permit the commissioner, or his authorized 201
representatives, to enter and inspect their premises and delivery 202
vehicles, and to audit their records and written operating procedures, at 203
reasonable times and in a reasonable manner. 204
[(g)] (h) Before denying, suspending, revoking or refusing to renew a 205
registration, or before issuing a letter of reprimand or placing a 206
Substitute Bill No. 5225

LCO 8 of 20

registrant on probationary status, the commissioner shall afford the 207
applicant or registrant an opportunity for a hearing in accordance with 208
the provisions of chapter 54. Notice of such hearing may be given by 209
certified mail. The commissioner may subpoena witnesses and require 210
the production of records, papers and documents pertinent to such 211
hearing. 212
[(h)] (i) No [wholesaler or] manufacturer or wholesaler shall sell any 213
drugs except to the state or any political subdivision thereof, to another 214
manufacturer or wholesaler, to any hospital recognized by the state as a 215
general or specialty hospital, to any institution having a full -time 216
pharmacist who is actively engaged in the practice of pharmacy in such 217
institution not less than thirty -five hours a week, to a chronic and 218
convalescent nursing home having a pharmacist actively engaged in the 219
practice of pharmacy based upon the ratio of one-tenth of one hour per 220
patient per week but not less than twelve hours per week, to a practicing 221
physician, podiatrist, dentist, optometrist or veterinarian, to a licensed 222
pharmacy or a store to which a permit to sell nonlegend drugs has been 223
issued as provided in section 20 -624 or to an authorized entity, as 224
defined in section 19a-909, as amended by this act , that has established 225
a medical protocol with a prescribing practitioner pursuant to section 226
19a-909, as amended by this act , provided drugs sold to an authorized 227
entity shall be limited to epinephrine, as defined in section 19a -909, as 228
amended by this act. [The commissioner may adopt such regulations as 229
are necessary to administer and enforce the provisions of this section.] 230
[(i)] (j) (1) Each registered manufacturer or wholesaler of drugs shall 231
operate a system to identify suspicious orders of controlled substances 232
and shall immediately inform the Director of the Drug Control Division 233
of suspicious orders. Suspicious orders include, but are not limited to, 234
orders of unusual size, orders deviating substantially from a normal 235
pattern and orders of unusual frequency. Each registered manufacturer 236
or wholesaler of drugs shall also send the Drug Control Division a copy 237
of any suspicious orders submitted to the federal Drug Enforcement 238
Administration pursuant to 21 CFR 1301.74. 239
Substitute Bill No. 5225

LCO 9 of 20

(2) Each registered manufacturer or wholesaler of drugs that, based 240
on concerns of potential diversion, ceases or declines distribution of any 241
schedule II, III, IV or V controlled substance to a pharmacy, as defined 242
in section 20 -594, or to a practitioner, as defined in section 21a -316, in 243
the state of Connecticut shall report the name of the pharmacy or 244
practitioner, location of the pharmacy or practitioner and the reasons for 245
ceasing or declining distribution of such controlled substance in writing 246
to the Director of the Drug Control Division, or to an electronic system 247
designated by the Drug Control Division, not later than five business 248
days after ceasing or declining distribution of such controlled substance. 249
(k) The commissioner may adopt regulations, in accordance with the 250
provisions of chapter 54, to administer and enforce the provisions of this 251
section. 252
[(j)] (l) Any person who violates any provision of this section shall be 253
fined not more than five hundred dollars or imprisoned not more than 254
six months, or both. 255
Sec. 2. Subdivision (4) of subsection (a) of section 19a-909 of the 2026 256
supplement to the general statutes is repealed and the following is 257
substituted in lieu thereof (Effective October 1, 2026): 258
(4) "Authorized entity" means any for -profit or nonprofit entity or 259
organization that employs at least one person with training. 260
"Authorized entity" does not include the state or any political 261
subdivision thereof authorized to purchase epinephrine pursuant to 262
subsection [(h)] (i) of section 21a -70, as amended by this act , a local or 263
regional board of education required to maintain epinephrine pursuant 264
to subdivision (2) of subsection (d) of section 10 -212a or a licensed or a 265
certified ambulance service required to be equipped with epinephrine 266
cartridge injectors pursuant to subsection (b) of section 19a-197a. 267
Sec. 3. Section 21a -248 of the general statutes is repealed and the 268
following is substituted in lieu thereof (Effective June 15, 2026): 269
(a) (1) A licensed manufacturer or wholesaler may sell and dispense 270
Substitute Bill No. 5225

LCO 10 of 20

controlled drugs to any of the following-named persons, but in the case 271
of schedule II drugs only on an official written order or electronically 272
through the Drug Enforcement Agency's Controlled Substance 273
Ordering System: [(1)] (A) To a manufacturer, wholesaler or pharmacist; 274
[(2)] (B) to a physician, dentist or veterinarian; [(3)] (C) to a person in 275
charge of a hospital, incorporated college or scientific institution, but 276
only for use by or in that hospital, incorporated college or scientific 277
institution for medical or scientific purposes; [(4)] (D) to a person in 278
charge of a laboratory, but only for use in that laboratory for scientific 279
and medical purposes; and [(5)] (E) to any registrant as defined in 280
section 21a-240. 281
[(b)] (2) A licensed manufacturer or wholesaler may sell controlled 282
drugs only to registrants when permitted under federal and state laws 283
and regulations. 284
(3) Notwithstanding the provisions of subdivisions (1) and (2) of this 285
subsection, no licensed manufacturer or wholesaler shall sell or 286
dispense a controlled drug directly to another person with actual 287
knowledge that such other person intends to use the controlled drug to 288
execute a sentence of death imposed by a court. 289
[(c)] (b) An official order for any schedule I or II drug shall be signed 290
by the person giving such order or by such person's authorized agent 291
and such order shall be presented to the person who sells or dispenses 292
the drug or drugs named therein as provided by federal law. If such 293
order is accepted by such person, each party to the transaction shall 294
preserve such party's copy of such order for a period of three years in 295
such a way so as to be readily accessible for inspection by any public 296
officer or employee engaged in the enforcement of this chapter. 297
[(d)] (c) The manufacturer or wholesaler shall keep records of all sales 298
and dispensing of controlled drugs and shall comply fully with 299
applicable provisions of the federal controlled drug laws and the federal 300
food and drug laws, and the state food, drug and cosmetic laws in such 301
sale or dispensing of controlled drugs. 302
Substitute Bill No. 5225

LCO 11 of 20

[(e)] (d) Possession or control of controlled drugs obtained as 303
authorized by this section shall be lawful only if obtained in the regular 304
course of the business, occupation, profession, employment or duty of 305
the possessor. 306
[(f)] (e) (1) A person in charge of a hospital, incorporated college or 307
scientific institution, or of a laboratory, or in the employ of this state or 308
of any other state, or of any political subdivision thereof, and a master 309
or other proper officer of a ship or aircraft, who obtains controlled drugs 310
under the provisions of this section or otherwise, shall not administer, 311
or dispense, or otherwise use such drugs within this state, except within 312
the scope of such person's, master's or officer's employment or official 313
duty, and then only for scientific or medicinal purposes or for the 314
purposes of research or analysis and subject to the provisions of this 315
chapter. 316
(2) The provisions of subdivision (1) of this subsection shall not be 317
construed to authorize any person to obtain, administer, dispense or 318
otherwise use a controlled drug to execute a sentence of death imposed 319
by a court. 320
Sec. 4. Subsection (a) of section 20 -579 of the general statutes is 321
repealed and the following is substituted in lieu thereof (Effective October 322
1, 2026): 323
(a) The commission may refuse to authorize the issuance of a 324
temporary permit to practice pharmacy, may refuse to authorize the 325
issuance or renewal of a license to practice pharmacy, a license to 326
operate a pharmacy or a registration of a pharmacy intern or pharmacy 327
technician, and may revoke, suspend or place conditions on a license or 328
temporary permit to practice pharmacy, a license to operate a pharmacy, 329
or a registration of a pharmacy intern or a pharmacy technician, and 330
may assess a civil penalty of up to one thousand dollars per violation of 331
any provision of this chapter or take other action permitted in 332
subdivision (7) of section 21a-7 if the applicant or holder of the license, 333
temporary permit or registration: (1) Has violated a statute or regulation 334
Substitute Bill No. 5225

LCO 12 of 20

relating to drugs, devices or the practice of pharmacy of this state, any 335
state of the United States, the United States, the District of Columbia, the 336
Commonwealth of Puerto Rico, any territory or insular possession 337
subject to the jurisdiction of the United States or a foreign jurisdiction; 338
(2) has been convicted of violating any criminal statute relating to drugs, 339
devices or the practice of pharmacy of this state, any state of the United 340
States, the United States, the District of Columbia, the Commonwealth 341
of Puerto Rico, any territory or insular possession subject to the 342
jurisdiction of the United States or a foreign jurisdiction; (3) has been 343
disciplined by, or is the subject of pending disciplinary action or an 344
unresolved complaint before, the duly authorized pharmacy 345
disciplinary agency of any state of the United States, the United States, 346
the District of Columbia, the Commonwealth of Puerto Rico, any 347
territory or insular possession subject to the jurisdiction of the United 348
States or a foreign jurisdiction; (4) has been refused a license or 349
registration or renewal of a license or registration by any state of the 350
United States, the United States, the District of Columbia, the 351
Commonwealth of Puerto Rico, any territory or insular possession 352
subject to the jurisdiction of the United States or a foreign jurisdiction 353
based on grounds that are similar to grounds on which Connecticut 354
could refuse to issue or renew such a license or registration; (5) has 355
illegally possessed, diverted, sold or dispensed drugs or devices; (6) 356
abuses or excessively uses drugs, including alcohol; (7) has made false, 357
misleading or deceptive representations to the public or the 358
commission; (8) has maintained exclusive telephone lines to, has 359
maintained exclusive electronic communication with, or has exclusive 360
access to computers located in offices of prescribing practitioners, 361
nursing homes, clinics, hospitals or other health care facilities; (9) has 362
substituted drugs or devices except as permitted in section 20 -619; (10) 363
has accepted, for return to regular stock, any drug already dispensed in 364
good faith or delivered from a pharmacy, and exposed to possible and 365
uncontrolled contamination or substitution; (11) has accepted, for return 366
to general inventory or regular stock, any drug sold or delivered to a 367
patient, unless accepting such drug for return to general inventory or 368
regular stock is otherwise permitted or required by law; (12) has split 369
Substitute Bill No. 5225

LCO 13 of 20

fees for professional services, including a discount or rebate, with a 370
prescribing practitioner or an administrator or owner of a nursing home, 371
hospital or other health care facility; (13) has entered into an agreement 372
with a prescribing practitioner or an administrator or owner of a nursing 373
home, hospital or other health care facility for the compounding or 374
dispensing of secret formula or coded prescriptions; (14) has performed 375
or been a party to a fraudulent or deceitful practice or transaction; (15) 376
has presented to the commission a diploma, license or certificate 377
illegally or fraudulently obtained, or obtained from a college or school 378
of pharmacy not approved by the commission; (16) has performed 379
incompetent or negligent work; (17) while holding such license, 380
temporary permit or registration, has dispensed or distributed a drug or 381
device directly to another person with actual knowledge that such other 382
person intended to use such drug or device to execute a sentence of 383
death imposed by a court; (18) has falsified a continuing education 384
document submitted to the commission or department or a certificate 385
retained in accordance with the provisions of subsection (d) of section 386
20-600; [(18)] (19) has permitted a person not licensed to practice 387
pharmacy in this state to practice pharmacy in violation of section 20 -388
605, to use a pharmacist license or pharmacy display document in 389
violation of section 20 -608, or to use words, displays or symbols in 390
violation of section 20 -609; [(19)] (20) has failed to maintain the entire 391
pharmacy premises, its components and contents in a clean, orderly and 392
sanitary condition; [(20)] (21) has failed to demonstrate adherence to 393
applicable provisions of United States Pharmacopeia, Chapter 797, 394
Pharmaceutical Compounding - Sterile Preparations, as amended from 395
time to time; or [(21)] (22) has failed to demonstrate adherence to 396
applicable provisions of United States Pharmacopeia, Chapter 795, 397
Pharmaceutical Compounding – Nonsterile Preparations, as amended 398
from time to time. 399
Sec. 5. Subsection (c) of section 20 -593 of the general statutes is 400
repealed and the following is substituted in lieu thereof (Effective October 401
1, 2026): 402
(c) The commission shall not grant a renewal license to an applicant 403
Substitute Bill No. 5225

LCO 14 of 20

who (1) has not held a license authorized by the commission within five 404
years of the date of application unless the applicant has passed an 405
examination satisfactory to the commission and has paid the fee 406
required in section 20-601, or (2) within the calendar year preceding the 407
date of application, dispensed or distributed a drug or device directly to 408
another person with actual knowledge that such other person intended 409
to use the drug or device to execute a sentence of death imposed by a 410
court. 411
Sec. 6. Subsection (d) of section 20 -613 of the general statutes is 412
repealed and the following is substituted in lieu thereof (Effective October 413
1, 2026): 414
(d) Nothing in sections 20-570 to 20-630, inclusive, shall be construed 415
to (1) prevent a prescribing practitioner from dispensing the prescribing 416
practitioner's own prescriptions to the prescribing practitioner's own 417
patients when authorized within the scope of the prescribing 418
practitioner's own practice and when done in compliance with sections 419
20-14c to 20 -14g, inclusive , or (2) authorize a person to dispense or 420
transfer a drug or device directly to another person with actual 421
knowledge that such other person intends to use the drug or device to 422
execute a sentence of death imposed by a court. 423
Sec. 7. Section 20 -613a of the general statutes is repealed and the 424
following is substituted in lieu thereof (Effective October 1, 2026): 425
(a) For the purposes of this section, "electronic questionnaire" means 426
any form in an electronic format that may require personal, financial or 427
medical information from a consumer or patient. 428
(b) In the absence of a documented patient evaluation that includes a 429
physical examination, any request for a controlled substance issued 430
solely on the results of answers to an electronic questionnaire shall be 431
considered to be issued outside the context of a valid practitioner -432
patient relationship and not be a valid prescription. 433
(c) Any request for a controlled substance to execute a sentence of 434
Substitute Bill No. 5225

LCO 15 of 20

death imposed by a court shall be considered to be issued outside the 435
context of a valid practitioner -patient relationship and not be a valid 436
prescription. 437
(d) The Commissioner of Consumer Protection may adopt 438
regulations, in accordance with chapter 54, concerning [such] requests 439
for controlled substances. [For the purposes of this section, "electronic 440
questionnaire" means any form in an electronic format that may require 441
personal, financial or medical information from a consumer or patient.] 442
Sec. 8. Subsection (a) of section 20 -629 of the general statutes is 443
repealed and the following is substituted in lieu thereof (Effective October 444
1, 2026): 445
(a) The commission may deny, revoke or suspend any certificate of 446
registration as a nonresident pharmacy for: 447
(1) Failure to comply with any requirement of this chapter or chapter 448
420b; 449
(2) Failure to comply with any federal or state statute or regulation 450
concerning drugs or the practice of pharmacy; 451
(3) Delivering in any manner into this state legend drugs or legend 452
devices that are adulterated or misbranded in violation of chapter 418; 453
[or] 454
(4) Delivering a legend drug or legend device directly to another 455
person with actual knowledge that such other person intends to use the 456
legend drug or legend device to execute a sentence of death imposed by 457
a court; or 458
[(4)] (5) Any disciplinary action taken against the nonresident 459
pharmacy by any state or federal agency. 460
Sec. 9. Subsections (d) to (n), inclusive, of section 20 -633b of the 2026 461
supplement to the general statutes are repealed and the following is 462
substituted in lieu thereof (Effective June 15, 2026): 463
Substitute Bill No. 5225

LCO 16 of 20

(d) (1) A sterile compounding pharmacy may only provide patient-464
specific sterile pharmaceuticals to patients, to practitioners of medicine, 465
osteopathy, podiatry, dentistry or veterinary medicine, or to an acute 466
care or long -term care hospital or health care facility licensed by the 467
Department of Public Health. 468
(2) If a sterile compounding pharmacy provides sterile 469
pharmaceuticals without a patient -specific prescription or medical 470
order, the sterile compounding pharmacy shall also obtain a certificate 471
of registration from the Department of Consumer Protection pursuant 472
to section 21a -70, as amended by this act, and any required federal 473
license or registration. A sterile compounding pharmacy may prepare 474
and maintain on -site inventory of sterile pharmaceuticals no greater 475
than a thirty -day supply, calculated from the completion of 476
compounding, which thirty -day period shall include the period 477
required for third -party analytical testing, to be performed in 478
accordance with the USP chapters. 479
(3) Nothing in subdivision (1) or (2) of this subsection shall be 480
construed to authorize a sterile compounding pharmacy to provide a 481
sterile pharmaceutical directly to another person with actual knowledge 482
that such other person intends to use the sterile pharmaceutical to 483
execute a sentence of death imposed by a court. 484
(e) (1) If a sterile compounding pharmacy plans to remodel any area 485
utilized for the compounding of sterile pharmaceuticals or adjacent 486
space, relocate any space utilized for the compounding of sterile 487
pharmaceuticals or upgrade or conduct a nonemergency repair to the 488
heating, ventilation, air conditioning or primary or secondary 489
engineering controls for any space utilized for the compounding of 490
sterile pharmaceuticals, the sterile compounding pharmacy shall notify 491
the Department of Consumer Protection, in writing, not later than forty-492
five days prior to commencing such remodel, relocation, upgrade or 493
repair. Such written notification shall include a plan for such remodel, 494
relocation, upgrade or repair and such plan shall be subject to 495
department review and approval. If a sterile compounding pharmacy 496
Substitute Bill No. 5225

LCO 17 of 20

makes an emergency repair, the sterile compounding pharmacy shall 497
notify the department of such emergency repair, in writing, not later 498
than twenty-four hours after such repair is commenced. 499
(2) If the USP chapters require sterile recertification after such 500
remodel, relocation, upgrade or repair, the sterile compounding 501
pharmacy shall provide a copy of such sterile compounding pharmacy's 502
sterile recertification to the Department of Consumer Protection not 503
later than five days after the sterile recertification approval. The 504
recertification shall only be performed by an independent licensed 505
environmental monitoring entity. 506
(f) A sterile compounding pharmacy shall report, in writing, to the 507
Department of Consumer Protection any known violation or 508
noncompliance with viable and nonviable environmental sampling 509
testing, as defined in the USP chapters, not later than the end of the next 510
business day after discovering such violation or noncompliance. 511
(g) (1) If a sterile compounding pharmacy initiates a recall of sterile 512
pharmaceuticals that were dispensed pursuant to a patient -specific 513
prescription or medical order, the sterile compounding pharmacy shall 514
notify each patient or patient care giver, the prescribing practitioner and 515
the Department of Consumer Protection of such recall not later than 516
twenty-four hours after such recall was initiated. 517
(2) If a sterile compounding pharmacy initiates a recall of sterile 518
pharmaceuticals that were not dispensed pursuant to a patient -specific 519
prescription or a medical order, the sterile compounding pharmacy 520
shall notify (A) each purchaser of such sterile pharmaceuticals, to the 521
extent such sterile compounding pharmacy possesses contact 522
information for each such purchaser, (B) the Department of Consumer 523
Protection, and (C) the federal Food and Drug Administration of such 524
recall not later than the end of the next business day after such recall 525
was initiated. 526
(h) Each sterile compounding pharmacy shall prepare and maintain 527
a policy and procedure manual. The policy and procedure manual shall 528
Substitute Bill No. 5225

LCO 18 of 20

comply with the USP chapters. 529
(i) Each sterile compounding pharmacy shall report to the 530
Department of Consumer Protection any administrative or legal action 531
commenced against such sterile compounding pharmacy by any state 532
or federal regulatory agency or accreditation entity not later than five 533
business days after receiving notice of the commencement of such 534
action. 535
(j) Notwithstanding the provisions of subdivision (2) of subsection (b) 536
of this section, a sterile compounding pharmacy that is a nonresident 537
pharmacy shall submit to the Department of Consumer Protection an 538
inspection report from a government agency with regulatory oversight 539
over such nonresident pharmacy or from a third -party entity with 540
expertise in sterile compounding. Such report shall demonstrate that 541
such nonresident pharmacy is in compliance with the standards 542
required in the most recent United States Pharmacopeia, Chapter 797, 543
as amended from time to time. Such nonresident pharmacy shall submit 544
to the department a copy of the most recent inspection report with such 545
nonresident pharmacy's initial nonresident pharmacy application, 546
which inspection report shall be dated by the inspector and evidence 547
that the inspection was performed during the six -month period 548
immediately preceding the submission date of such initial application. 549
Not later than June thirtieth of each even -numbered calendar year 550
following such initial application, such nonresident pharmacy shall 551
submit to the department a new inspection report demonstrating that 552
such nonresident pharmacy remains in compliance with the standards 553
required in the most recent United States Pharmacopeia, Chapter 797, 554
as amended from time to time, which inspection report shall be dated 555
by the inspector and indicate that the inspection was performed not 556
earlier than January first of such even -numbered calendar year. 557
Notwithstanding the provisions of this subsection, a sterile 558
compounding pharmacy that is a nonresident pharmacy shall not be 559
required to submit more than one inspection report during the calendar 560
year after the nonresident pharmacy is issued an initial registration. 561
Substitute Bill No. 5225

LCO 19 of 20

(k) A practitioner, as specified in subdivision (1) of subsection (d) of 562
this section, a hospital or a health care facility that receives sterile 563
pharmaceuticals shall report any errors related to such dispensing or 564
any suspected adulterated sterile pharmaceuticals to the Department of 565
Consumer Protection. 566
(l) (1) For purposes of this subsection, a "designated pharmacist" 567
means a pharmacist responsible for overseeing the compounding of 568
sterile pharmaceuticals and the application of the USP chapters, as said 569
chapters pertain to sterile compounding. 570
(2) Any pharmacy licensed pursuant to section 20 -594 that provides 571
sterile pharmaceuticals shall notify the department of such pharmacy's 572
designated pharmacist. 573
(3) The designated pharmacist shall be responsible for providing 574
proof such designated pharmacist has completed a program approved 575
by the commissioner that demonstrates the competence necessary for 576
the compounding of sterile pharmaceuticals, in compliance with all 577
applicable federal and state statutes and regulations. 578
(4) The designated pharmacist shall immediately notify the 579
department whenever such designated pharmacist ceases such 580
designation. 581
(5) Nothing in this section shall prevent a designated pharmacist 582
from being the pharmacy manager. 583
(m) Notwithstanding the provisions of this section, (1) the addition 584
of a flavoring agent in accordance with subsections (a) and (b) of section 585
20-617a shall be exempt from the requirements of United States 586
Pharmacopeia, Chapter 795, Pharmaceutical Compounding – 587
Nonsterile Preparations, and Chapter 800, Hazardous Drugs, as both 588
may be amended from time to time , and (2) no sterile compounding 589
pharmacy shall sell or transfer a sterile pharmaceutical directly to 590
another person with actual knowledge that such other person intends to 591
use the sterile pharmaceutical to execute a sentence of death imposed by 592
Substitute Bill No. 5225

LCO 20 of 20

a court. 593
(n) The Commissioner of Consumer Protection may adopt 594
regulations, in accordance with chapter 54, to implement the provisions 595
of subsections (a) to (m), inclusive, of this section. 596
This act shall take effect as follows and shall amend the following
sections:

Section 1 October 1, 2026 21a-70
Sec. 2 October 1, 2026 19a-909(a)(4)
Sec. 3 June 15, 2026 21a-248
Sec. 4 October 1, 2026 20-579(a)
Sec. 5 October 1, 2026 20-593(c)
Sec. 6 October 1, 2026 20-613(d)
Sec. 7 October 1, 2026 20-613a
Sec. 8 October 1, 2026 20-629(a)
Sec. 9 June 15, 2026 20-633b(d) to (n)

GL Joint Favorable Subst.
JUD Joint Favorable